Mylan recalls drug after problem uncovered with Indian supplier

A problem with a supplier in India has led Mylan ($MYL) to voluntarily recall a cancer drug in Canada. The maker of generic drugs has recalled one lot of methotrexate injection after the discovery of particulate in a unit. Mylan notified Health Canada of the potential manufacturing issue after it was uncovered during an inspection by a regulator of Onco Therapies, a unit of India's Strides Arcolab and one of its suppliers. Mylan made the decision to recall the product after its own investigation found the same problem in a sample of its product. Health Canada said it is looking at other Onco Therapies products shipped to Canada to see if there are any other issues. Report

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.